The HTRA2 Knockout Jurkat Polyclonal Cells provided by Ascent Research constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphoblastoid cell line. Through targeted disruption of the HTRA2 gene, this product offers a heterogeneous pool of cells carrying diverse loss-of-function alleles, enabling researchers to investigate HTRA2-dependent mechanisms without clonal selection bias. The polyclonal format reflects the natural variability in gene editing outcomes, making it suitable for functional genomic studies, pool-based screening approaches, and experiments where complete genetic uniformity is not required. These cells serve as a robust model for dissecting the role of HTRA2 in mitochondrial biology and apoptotic signaling.
Jurkat cells are an immortalized T lymphocyte line originally isolated from the peripheral blood of a 14-year-old male with acute T cell leukemia. They are extensively employed in immunology and cancer research to study T cell receptor signal transduction, apoptosis induction, and HIV infection dynamics. Notably, Jurkat cells are highly susceptible to various apoptotic stimuli, including chemotherapeutic agents and death receptor ligands, and they possess a fully functional intrinsic apoptosis machinery. This makes them an ideal host system for examining the mitochondrial pathway of apoptosis, where the HTRA2 protease operates. Their well-characterized signaling networks allow precise interrogation of genotype-phenotype relationships following gene knockout.
HTRA2, also known as Omi, is a nuclear-encoded mitochondrial serine protease that resides in the intermembrane space. Under basal conditions, HTRA2 functions in mitochondrial protein quality control by degrading misfolded or damaged proteins, cooperating with the chaperone mortalin. Upon receipt of apoptotic signals such as UV radiation or the topoisomerase inhibitor etoposide, BAX and BAK induce mitochondrial outer membrane permeabilization, leading to the release of cytochrome c, SMAC/DIABLO, and HTRA2 into the cytosol. Cytosolic HTRA2 promotes apoptosis primarily by binding and proteolytically cleaving IAP family members (XIAP, cIAP1, cIAP2), thereby relieving caspase inhibition. This enables activation of executioner caspases, including caspase-3 and caspase-7, and subsequent cellular demolition. Additionally, HTRA2 intersects with the PINK1/Parkin pathway, where it is regulated by PINK1 and contributes to mitochondrial homeostasis, linking its dysfunction to Parkinson disease pathogenesis.
The use of Jurkat cells as the host for HTRA2 knockout is particularly informative due to their reliance on intact apoptotic machinery for cell fate decisions. Disruption of HTRA2 in this T lymphoblast context allows researchers to dissect the protease’s specific contributions to intrinsic apoptosis downstream of mitochondrial outer membrane permeabilization, independent of other IAP antagonists like SMAC/DIABLO. Moreover, the polyclonal nature of the knockout pool facilitates the study of partial versus complete loss-of-function effects, which may mirror the variable penetrance observed in neurodegenerative conditions. By combining this knockout model with Jurkat’s established utility in examining protein-protein interactions and post-translational modifications, investigators can probe HTRA2 interactions with XIAP, PINK1, and mitochondrial chaperones under physiologically relevant signaling conditions.
This HTRA2 knockout Jurkat cell pool supports a broad array of experimental workflows. Typical applications include quantitative assessment of apoptosis using flow cytometry with Annexin V and propidium iodide staining, western blot analysis of cleaved caspase-3, caspase-7, and HTRA2 levels, and co-immunoprecipitation to validate HTRA2?CXIAP complexes. The model is also amenable to drug sensitivity assays, where cells can be challenged with etoposide or other chemotherapeutics to evaluate HTRA2-dependent cell death, and to Parkinson disease modeling through pharmacologic manipulation of the PINK1/Parkin axis. Immunofluorescence microscopy with antibodies against Tom20 and HTRA2 can reveal mitochondrial morphology alterations. These cells are suitable for RT-qPCR profiling of downstream factors such as ??-casein or for genetic screens seeking modifiers of HTRA2-mediated apoptosis. For inquiries regarding lot-specific performance or custom applications, please contact Ascent Research.
